Analysis of anti-cancer chemicals and pharmaceutical formulations

Ended Definitive Contract Awarded Last action

Contract number
HHSN261200722003C
Awardee
Awarding agency
Obligated
$3,110,741

Award facts

Opportunity
  • N02CM6703665 Solicitation number
Contract value 39% obligated
  • $3,984,307.00 Current, with exercised options
  • $7,910,623.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
Not on record
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Menlo Park, CA 94025, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action 15 $0
Other Administrative Action 14 $0
Other Administrative Action 13 $0
Other Administrative Action 12 $0
Other Administrative Action 11 · Other functions analysis of anti-cancer chemicals and pharmaceutical formulations--DTP-10-054, SRI international, NO2-CM-72203 $0
Other Administrative Action 10 $0
Funding Only Action 9 $80,400
Funding Only Action 8 $50,000
Other Administrative Action 7 $0
Funding Only Action 6 $99,995
Funding Only Action 5 $410,526
Funding Only Action 4 · Analysis of anti-cancer chemicals and pharmaceutical formulations--DTP-10-054, SRI international, NO2-CM-72203 $200,000
Funding Only Action 3 $389,784
Exercise an Option 2 $1,053,287
Exercise an Option 1 $192,725
Original award $634,024
Show all 16

About this award

Written by GovTribe AI ·

This is a $7,910,623.00 cost-plus-fixed-fee contract awarded by the National Cancer Institute (part of the U.S. Department of Health and Human Services) to SRI International, a non-profit research and development institute. The contract is for analysis of anti-cancer chemicals and pharmaceutical formulations. It does not have a small business set-aside designation. SRI International frequently serves as a prime contractor and subcontractor on research and development contracts and grants with various federal agencies, including the Department of Defense, NASA, and the National Institutes of Health, where it leverages its expertise across disciplines such as biomedical sciences, computing, and defense technologies. This contract represents part of SRI International's work supporting the National Cancer Institute's research and drug development programs.

Quick answers

Who was awarded contract HHSN261200722003C?

HHSN261200722003C was awarded to Sri International by National Cancer Institute (National Institutes of Health) on June 1, 2007.

How much is contract HHSN261200722003C worth?

The government has obligated $3,110,741 on HHSN261200722003C. Its current value, with exercised options, is $3,984,307. Its potential value, with all options, is $7,910,623.

Was contract HHSN261200722003C competed?

The extent of competition for HHSN261200722003C was full and open competition. The government received 4 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login